Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Free Cash Flow (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Free Cash Flow for 6 consecutive years, with -$28.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 68.1% to -$28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$83.3 million through Dec 2025, down 88.53% year-over-year, with the annual reading at -$83.3 million for FY2025, 88.53% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$28.6 million at Janux Therapeutics, down from -$12.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was $5.6 million in Q1 2021, with the low at -$28.6 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$12.3 million, with a median of -$12.7 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 581.6% in 2021, then surged 81.34% in 2024.
  • Over 5 years, Free Cash Flow stood at -$11.1 million in 2021, then plummeted by 54.54% to -$17.2 million in 2022, then soared by 49.34% to -$8.7 million in 2023, then crashed by 95.93% to -$17.0 million in 2024, then tumbled by 68.1% to -$28.6 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$28.6 million, -$12.9 million, and -$24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.